| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Ribociclib |
| Brand | Kisqali® |
| Indication | Is indicated in combination with an aromatase inhibitor or fulvestrant for the treatment of pre-, peri- and post-menopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer as initial endocrine therapy, or in women who have received prior endocrine therapy: |
| Assessment Process | |
| Rapid review commissioned | 11/06/2019 |
| Rapid review completed | 11/07/2019 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that ribociclib not be considered for reimbursement at the submitted price. |
This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
The HSE has approved reimbursement following confidential price negotiations September 2020.
